Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M190,836Revenue (TTM) $M49,995Net Margin (%)13.6Altman Z-Score2.3
Enterprise Value $M220,921EPS (TTM) $2.8Operating Margin %17.3Piotroski F-Score4
P/E(ttm)29.3Beneish M-Score-2.7Pre-tax Margin (%)15.6Higher ROA y-yN
Price/Book2.710-y EBITDA Growth Rate %-2.3Quick Ratio0.6Cash flow > EarningsY
Price/Sales3.95-y EBITDA Growth Rate %-4.1Current Ratio0.8Lower Leverage y-yN
Price/Free Cash Flow24.0y-y EBITDA Growth Rate %-20.0ROA % (ttm)5.1Higher Current Ratio y-yN
Dividend Yield %3.4PEG--ROE % (ttm)8.9Less Shares Outstanding y-yY
Payout Ratio %97.0Shares Outstanding M2,381ROIC % (ttm)7.8Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVSKen Fisher 2016-03-31 Add0.01%$71.11 - $86.21
($76.1)
$ 80.085%Add 1.59%6,287,099
NVSTweedy Browne 2016-03-31 Reduce-0.01%$71.11 - $86.21
($76.1)
$ 80.085%Reduce -1.87%237,664
NVSTom Gayner 2016-03-31 Buy 0.01%$71.11 - $86.21
($76.1)
$ 80.085%New holding3,700
NVSJohn Rogers 2016-03-31 Add$71.11 - $86.21
($76.1)
$ 80.085%Add 18.01%13,296
NVSMario Gabelli 2016-03-31 Reduce$71.11 - $86.21
($76.1)
$ 80.085%Reduce -7.10%6,865
NVSDodge & Cox 2016-03-31 Reduce$71.11 - $86.21
($76.1)
$ 80.085%Reduce -0.12%45,054,916
NVSDodge & Cox 2015-12-31 Reduce-0.06%$83.96 - $95.03
($88.53)
$ 80.08-10%Reduce -1.35%45,107,085
NVSTweedy Browne 2015-12-31 Reduce-0.02%$83.96 - $95.03
($88.53)
$ 80.08-10%Reduce -2.74%242,201
NVSKahn Brothers 2015-12-31 Reduce-0.02%$83.96 - $95.03
($88.53)
$ 80.08-10%Reduce -3.15%27,643
NVSJohn Rogers 2015-12-31 Buy 0.01%$83.96 - $95.03
($88.53)
$ 80.08-10%New holding11,267
NVSKen Fisher 2015-12-31 Add0.01%$83.96 - $95.03
($88.6)
$ 80.08-10%Add 0.92%6,188,893
NVSMario Gabelli 2015-12-31 Reduce$83.96 - $95.03
($88.53)
$ 80.08-10%Reduce -1.99%7,390
NVSDodge & Cox 2015-09-30 Reduce-0.2%$89.52 - $106.12
($99.32)
$ 80.08-19%Reduce -4.68%45,723,035
NVSKen Fisher 2015-09-30 Add0.02%$89.52 - $106.12
($99.32)
$ 80.08-19%Add 1.28%6,132,211
NVSKahn Brothers 2015-09-30 Add0.01%$89.52 - $106.12
($99.32)
$ 80.08-19%Add 1.42%28,543
NVSTweedy Browne 2015-09-30 Reduce-0.01%$89.52 - $106.12
($99.32)
$ 80.08-19%Reduce -2.04%249,022
NVSMario Gabelli 2015-09-30 Reduce$89.52 - $106.12
($99.32)
$ 80.08-19%Reduce -9.48%7,540
NVSDodge & Cox 2015-06-30 Reduce-0.19%$98.34 - $105.5
($102.32)
$ 80.08-22%Reduce -4.12%47,970,345
NVSKahn Brothers 2015-06-30 Reduce-0.05%$98.34 - $105.5
($102.32)
$ 80.08-22%Reduce -9.12%28,143
NVSTweedy Browne 2015-06-30 Reduce-0.02%$98.34 - $105.5
($102.32)
$ 80.08-22%Reduce -2.31%254,217
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVS is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NVS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Novartis Bioventures Ltd10% Owner 2014-09-22Buy325,000$15433.87view

Quarterly/Annual Reports about NVS:

    News about NVS:

    Articles On GuruFocus.com
    Samuel Isaly Trades in Health Care Stocks in 1st Quarter Apr 27 2016 
    Does Biotech’s Recent Bounce Have Legs? Apr 22 2016 
    Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 
    Dan Loeb's Third Point Portfolio Highly Concentrated Apr 01 2016 
    Daniel Loeb's Third Point Portfolio Highly Concentrated Mar 31 2016 
    Valeant's Share Price Continues to Decline Feb 05 2016 
    10 Fund Managers Are Totally Wrong on GlaxoSmithKline Jan 26 2016 
    Guru Stocks at 52-Week Lows Jan 26 2016 
    Berkshire Hathaway, Wells Fargo, China Mobile, Novartis, Bank of America Reach 52-Week Lows Jan 11 2016 
    Berkshire Hathaway, China Mobile, Novartis, Oracle, PetroChina Near 52-Week Lows Jan 04 2016 

    More From Other Websites
    Pfizer Offers Hope For Lower-Priced Cancer Drug Combos May 26 2016
    Novartis' CEO Says Company Open To Selling Its $14 Billion Stake In Roche 'If The Opportunity Were... May 25 2016
    Novartis willing to sell Roche stake without demanding premium - CEO May 25 2016
    Novartis willing to sell Roche stake without demanding premium - CEO May 25 2016
    Novartis willing to sell Roche stake without demanding premium - CEO May 25 2016
    4:02 am Novartis hosts its analyst and investor event; highlights pipeline and confirms Sandoz on... May 25 2016
    Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet... May 25 2016
    Novartis Filing for MabThera Biosimilar Accepted in the EU May 24 2016
    PDL’s Next Acquisition Target Focus Is on Hypertension May 24 2016
    Indian shares snap 4 days of losses on better corporate earnings May 24 2016
    Indian shares snap 4 days of losses on better corporate earnings May 24 2016
    Novartis' Cardiovascular Drug Gets Positive Recommendation May 23 2016
    Novartis executive exodus complicates drugmaker's rebuilding job May 23 2016
    Novartis sticks to $200 million FY Entresto forecast after recommendation May 23 2016
    The Impact of Novartis' New Business Model (NVS) May 23 2016
    Novartis executive exodus complicates drugmaker's rebuilding job May 23 2016
    Struggling Novartis heart drug boosted by new medical guidelines May 21 2016
    [$$] Colombia Threatens to Override Novartis’s Patent on Gleevec May 20 2016
    Novartis' Entresto® given strong Class I recommendation in both US and EU heart failure guidelines,... May 20 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)